DNA Topoisomerase II α, β : Trial Size
Code No: M052-3S
Datasheet:
FID:5541 | PATH:sites/default/files/datasheets/M052-3S.PDF
Target:
Topoisomerase IIAlpha/Beta
Background:
Eukaryotic DNA Topoisomerase II is a ubiquitous ATP-dependent type II Topoisomerase that play an important role in DNA replication, transcrIPPtion and recombination by changing the degree of superhelicity, catenation and knotting of topologically closed DNA molecules. Two isoforms of DNA Topoisomerases II have been reported in mammalian cells, Topoisomerase II and II. cDNA sequence of those isoforms reveals that both type II Topoisomerases are structurally and catalytically close. However, Topoisomerase II is expressed with no cell cycle dependence, whereas the expression of Topoisomerase II is cell cycle-regulated, peaking in G2-M phase and declining to a minimal level at the end of M phase. Topoisomerase II is polyubiquitinated and degraded preferentially in apoptosis induced human epithermoid carcinoma-derived cell line, MA1 cell, in an ATP-and-ubiquitin-dependent manner. Recent studies also indicated that this isoform is selectively cleaved during Fas-mediated T cell apoptosis and Fas-, Staurosporine- and Anisomycin-mediated Jurkat cell apoptosis.
Product Type:
Primary Antibody
Species Reactivities:
Human
Species Reactivities:
Mouse
Species Reactivities:
Rat
Related Products:
MD-17-3 Anti-Cyclin D1 (5D4)
K0062-3S Anti-Cyclin D1 (DCS-6)
K0063-3S Anti-Cyclin D2 (DCS-3)
K0064-3S Anti-Cyclin D2 (DCS-5)
K0013-3S Anti-Cyclin D3 (DCS-22)
MT-19-3S Anti-Cdc2Hs (5F6)
K0069-3S Anti-CDC6 (DCS-180)
K0070-3S Anti-CDC7 (DCS-342)
K0071-3S Anti-CDC25A (DCS-120)
K0072-3S Anti-CDC25A (DCS-121)
K0073-3S Anti-CDC25A (DCS-124)
MK-13-3S Anti-Cdk2 (8A12)
K0065-3S Anti-Cdk4 (DCS-156)
K0066-3S Anti-Cdk6 (DCS-83)
K0067-3 Anti-Cdk6 (DCS-130) available soon
K0068-3S Anti-Cdk7 (DCS-MO1)
K0077-3S Anti-p16INK4a (DCS-50)
K0078-3 Anti-p15INK4b (DCS-114) available soon
K0079-3S Anti-p18INK4c (DCS-118)
K0080-3S Anti-p19INK4d (DCS-100)
K0081-3S Anti-p21WAF1/CIPP1 (DCS-60)
K0082-3S Anti-p27KIPP1 (DCS-72)
K0084-3S Anti-p14ARF (DCS-240)
K0085-3S Anti-Cdh1 (DCS-266)
K0087-3S Anti-Chk2 (DCS-270)
K0088-3S Anti-Chk2 (DCS-273)
K0094-3S Anti-E2F-4 (TFE42)
K0095-3S Anti-DP-1 (TFD10)
M069-3S Anti-Mcm2 (4B8)
M038-3S Anti-Mcm3 (3A2)
M049-3S Anti-Mcm7 (4B4)
MK-15-1S Anti-RB (3H9)
M045-3S Anti-phospho RB (2C4)
K0091-3S Anti-RB2 (DCS-211)
References:
1) Pflugfelder M. et al. Proc. Natl. Acad. Sci. USA 85, 7177-7181 (1988)
2) Thomas D.Y. et al. Proc. Natl. Acad. Sci. USA 86, 9431-9435 (1989)
3) Tsutsui K. et al. J. Bio. Chem. 268, 19076-19083 (1993)
4) Nakajima T. et al. J. Biol. Chem. 271, 24842-24849 (1996)
5) Keeney S. et al. Cell 88, 375-384 (1997)
6) Bernard A. et al. Nature 386, 414-417 (1997)
7) Casiano C. et al. J. Exp. Med. 184, 765-770 (1996)
Formulation:
10 g IgG in 50 L volume of PBS containing 1% BSA, 10% glycerol and 0.1% sodium azide as preservative. Sodium azide has been reported to form potentially explosive lead or copper azide in plumbing. To prevent forming of these compounds, flush drains enough after disposing of solutions containing sodium azide.
Reactivity:
This antibody reacts with human, mouse and rat Topo II and on Western blot. The antibody detects 170 KD of human Topo II and 180 KD of human Topo II on Western blot with whole cell lysate from human cell line, for example, Jurkat and Raji
Intended Use:
For Research use only. Not for use in diagnostic procedure.
|